Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.55 |
| ▸ | BRD4 | O60885 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33268 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL29572486 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL12837999 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL1868013 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL10670441 | 0.81 | CREBBP (0.57) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL4130897 | 0.78 | MTNR1A (0.45) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL14946402 | 0.78 | GAA (0.47) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL29641564 | 0.78 | MTNR1A (0.45) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL19230496 | 0.78 | BRD4 (0.46) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL424121 | 0.78 | MTNR1A (0.45) | CREBBPBRD4TSHREP300GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4266390-A1 | ORGANIC LIGHT EMITTING DEVICE | Lg Chem, Ltd. (KR) | 2023-10-25 | — | — | EP | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008006648-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | LUPIN LTD. (IN) | 2007-06-28 | — | — | US | disclosed |
| US-7087597-B1 | Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1223170-B1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1223170-A1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | OR51E2, OR10J3, ORC3 | CREBBP 1097/4885BRD4 2437/4885TSHR 1036/4885 |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | TAAR1, TAAR5, MCHR1 | CREBBP 2243/4885BRD4 1652/4885TSHR 8/4885 |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | ACHE, BCHE, DDT | CREBBP 1699/4885BRD4 2651/4885TSHR 4454/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | CREBBP 2370/4885BRD4 47/4885TSHR 3955/4885 |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | REN, AGTR2, AGTR1 | CREBBP 1665/4885BRD4 1650/4885TSHR 2109/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | CREBBP 2136/4885BRD4 611/4885TSHR 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.